Dallas salon owner Shelley Luther discusses her comeback after being jailed for keeping her small business open during COVID ...

Citigroup upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) to a hold rating in a research note ...

Looking at options history for Regeneron Pharmaceuticals REGN we detected 8 trades. If we consider the specifics of each ...

Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...

Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

A biotech startup’s journey to unicorn status hinges on its leadership and the culture fostered within the organization. A ...

Politics will matter greatly for the biotechnology and healthcare sectors. On Thursday, President-elect Trump said that ...

The resubmitted sBLA will include results from Study C, which evaluated biologic-naive patients with uncontrolled CSU on antihistamines.